1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. 360iResearch Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. 360iResearch FPNV Positioning Matrix
2.3.2.1. 360iResearch Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support
3. Executive Summary
3.1. Outlook in the Brain Biomarkers Market
3.1.1. Biomarkers have the potential to improve the efficiency of the drug discovery and development process
3.1.2. Brain biomarkers are very late to the game as compared to its widespread use in oncology and cardiology arena
3.2. Opportunities in the Brain Biomarkers Market
3.3. Geographical Analysis in the Brain Biomarkers Market
4. Premium Insight
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
4.2.1.2. Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
4.2.1.3. Detection and interpretation to support clinical decisions and patient interventions
4.2.1.4. New product launch and comprehensive cluster for better treatment
4.2.2. Restraints
4.2.2.1. Extensive clinical validation is required to link a biomarker specifically to a Brain disease.
4.2.3. Opportunities
4.2.3.1. Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
4.2.3.2. Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
4.2.4. Challenges
4.2.4.1. Complexity of neuroinflammation exacerbated by substantial biological heterogeneity
4.3. Porter's Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
4.4.1. Product Development Pipeline
5. Global Brain Biomarkers Market: Product Estimates & Trend Analysis
5.1. Overview
5.2. Market Sizing & Forecasting
6. Global Brain Biomarkers Market: Indication Estimates & Trend Analysis
6.1. Overview
6.2. Market Sizing & Forecasting
7. Global Brain Biomarkers Market: End-Users Estimates & Trend Analysis
7.1. Overview
7.2. Market Sizing & Forecasting
8. Global Brain Biomarkers Market: Application Estimates & Trend Analysis
8.1. Overview
8.2. Market Sizing & Forecasting
9. Global Brain Biomarkers Market: Americas Estimates & Trend Analysis
9.1. Overview
9.2. Market Sizing & Forecasting
10. Global Brain Biomarkers Market: Europe, Middle East & Africa Estimates & Trend Analysis
10.1. Overview
10.2. Market Sizing & Forecasting
11. Global Brain Biomarkers Market: Asia-Pacific Estimates & Trend Analysis
11.1. Overview
11.2. Market Sizing & Forecasting
12. Competitive Landscape
12.1. 360iResearch FPNV Positioning Matrix for Global Brain Biomarkers Market
12.2. Market Vendor Ranking Analysis for Global Brain Biomarkers Market
12.3. Competitive News Feed Analysis for Global Brain Biomarkers Market
12.3.1. Mergers & Acquisitions
12.3.2. New Product Launches
12.3.3. Business Expansions
12.3.4. Partnerships, Agreements & Collaborations
13. Company Usability Profiles
13.1. Advanced Brain Monitoring
13.1.1. Business Overview
13.1.2. FPNV Scorecard
13.1.3. Business SWOT
13.1.4. Business Strategy
13.2. Electrical Geodesics
13.2.1. Business Overview
13.2.2. FPNV Scorecard
13.2.3. Business SWOT
13.2.4. Business Strategy
13.3. F. Hoffmann-La Roche Ltd.
13.3.1. Business Overview
13.3.2. FPNV Scorecard
13.3.3. Business SWOT
13.3.4. Business Strategy
13.4. Johnson & Johnson
13.4.1. Business Overview
13.4.2. FPNV Scorecard
13.4.3. Business SWOT
13.4.4. Business Strategy
13.5. Seimens Healthnineers
13.5.1. Business Overview
13.5.2. FPNV Scorecard
13.5.3. Business SWOT
13.5.4. Business Strategy
13.6. BrainScope
13.6.1. Business Overview
13.6.2. FPNV Scorecard
13.6.3. Business SWOT
13.6.4. Business Strategy
13.7. GE Healthcare
13.7.1. Business Overview
13.7.2. FPNV Scorecard
13.7.3. Business SWOT
13.7.4. Business Strategy
13.8. Lifesign LLC.
13.8.1. Business Overview
13.8.2. FPNV Scorecard
13.8.3. Business SWOT
13.8.4. Business Strategy
13.9. Natus Medical
13.9.1. Business Overview
13.9.2. FPNV Scorecard
13.9.3. Business SWOT
13.9.4. Business Strategy
13.10. NeuroVista
13.10.1. Business Overview
13.10.2. FPNV Scorecard
13.10.3. Business SWOT
13.10.4. Business Strategy
13.11. Nexus-DX
13.11.1. Business Overview
13.11.2. FPNV Scorecard
13.11.3. Business SWOT
13.11.4. Business Strategy
13.12. Qiagen N.V.
13.12.1. Business Overview
13.12.2. FPNV Scorecard
13.12.3. Business SWOT
13.12.4. Business Strategy
14. Appendix
14.1. Discussion Guide
14.2. Top Reports
14.2.1. Global Travel Management Solution Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
14.2.2. Global Managed Content as a Service Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
14.2.3. Global Electronic Data Interchange Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
14.2.4. Global Online Personals Dating Services Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
14.3. Author Details